 |
Medytox.(photo=medytox) |
[Alpha Biz= Reporter Kim Jisun] Medytox announced on the 12th that its Osong Plant 3 has received approval from Ukraine's medical device regulatory authority (UCMCP) as a new manufacturing facility for its hyaluronic acid (HA) filler 'Neuramis'. This approval, pursued to expand exports to Ukraine and neighboring regions, will enable the first production of Neuramis for export at Osong Plant 3, giving a boost to Medytox's efforts in the global market.
Previously, Medytox had been producing Neuramis for export exclusively at its Ochang Plant 1. However, with increasing demand for fillers in Ukraine and nearby regions, the company decided to expand its production capacity and sought approval for the Osong Plant 3, which is capable of large-scale manufacturing.
With this approval, Medytox plans to produce three Neuramis products—'Neuramis Lidocaine', 'Neuramis Deep Lidocaine', and 'Neuramis Volume Lidocaine'—at Osong Plant 3 for export to Ukraine. Ukraine is known as a strategic hub for entering the CIS and Eastern European markets, with the filler market in the country estimated to be worth around $13 million (approximately 18 billion KRW).
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
